



**MOLECULAR
DIAGNOSTICS MARKETS**
***(SAMPLE COPY, NOT FOR
RESALE)***

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	15
1.1	Statement of Report	15
1.2	About This Report	15
1.3	Scope of the Report	15
1.4	Objectives	16
1.5	Methodology	17
1.6	Executive Summary	18
2.	Introduction to Molecular Diagnostics and PCR Technology	22
2.1	Introduction to Genomics and Its Opportunity	22
2.2	Genetic Variability and Disease	24
2.3	Impact of the Human Genome Project on Molecular Diagnostics	24
2.4	Key Considerations for Molecular Diagnostics	26
2.5	Molecular Diagnostics in the Post-Genomic Era	27
2.6	Advances in Molecular Diagnostics Technologies	30
2.7	Molecular Diagnostics Testing Technologies and Platforms	33
2.7.1	Amplification Technologies	33
2.7.1.1	PCR and PCR Derivative Platforms	34
2.7.1.2	Multiple Displacement Amplification	39
2.7.1.3	Multiple Annealing and Looping-based Amplification Cycles	40
2.7.1.4	Whole Genome Amplification	40
2.7.1.5	Nucleic Acid Sequence-based Amplification	40
2.7.1.6	Ligase Chain Reaction	41
2.7.1.7	Branched DNA	41
2.7.1.8	Bio-Barcode Amplification Assay	42
2.7.2	Detection of Amplified Gene Products	42
2.7.2.1	High Resolution Melting Analysis	43
2.7.2.2	Microparticle-based Flow Cytometry	43
2.7.3	DNA and Oligonucleotide Microarrays and Chips	44
2.7.3.1	Array Comparative Genomic Hybridization	46
2.7.4	Gene Sequencing	47
2.7.4.1	Sanger Sequencing	47
2.7.4.2	Next Generation Sequencing	47
2.7.5	Fluorescence in situ Hybridization	52
2.8	PCR Reagents	53
2.9	Basic Molecular Testing Work Flow	53
2.10	Techniques	54
2.11	Advances in Automated Testing	54
3.	Business Landscape for the Molecular Diagnostics Market Sectors	55
3.1	Market Overview	55
3.2	Molecular Diagnostics Market: Size, Growth, Share, and Competitors	59
3.2.1	Global Molecular Diagnostics Market	59
3.2.2	U.S. Molecular Diagnostics Market	61
3.2.3	Market Share	63
3.2.4	Competitive Environment	66
3.2.5	Marketing Strategies	68
3.3	Snapshot of Molecular Diagnostics Industry Structure	68
3.4	Commercialization and Market Penetration Strategies	69
3.4.1	Partnerships	70
3.5	Market Drivers and Restraints	71
3.6	Market and Technology Trends	73
3.6.1	Market Trends	73

3.6.2	Technology Trends	74
3.7	Strategic Recommendations	75
3.8	What are the Challenges for the Future?	77
3.9	What New Trends are in the Future?	78
3.10	Recent Industry Activity	78
3.10.1	M&A Activity	78
3.10.2	License Agreements and Partnerships	80
3.11	Key Areas Impacting Future of Molecular Diagnostics	82
3.11.1	Pharmacogenetics and Pharmacogenomics	82
3.11.1.1	Current Applications for Pharmacogenetics and Pharmacogenomics	84
3.11.1.2	Pharmacogenomics and Personalized Medicine in MDx Infectious Disease Testing	85
3.11.1.3	Companion Diagnostics and Personalized Medicine in the Oncology Sector	86
3.11.2	Toxicogenomics	87
3.11.3	Multiplex Molecular Diagnostics	87
3.11.4	Point of Care Readers and Assays	87
3.11.5	Next Generation Sequencing	88
3.12	Intellectual Property Rights	90
3.12.1	New Patents	91
3.12.2	Current Patent Disputes	92
4.	Overview of Clinical Molecular Diagnostic Platforms on the Market	93
4.1	Abbott	94
4.1.1	m2000 RealTime System	94
4.2	Affymetrix Gene Profiling Solutions	94
4.2.1	GeneChip System 3000Dx v.2	95
4.2.2	Gene Profiling Array cGMP U133 P2	95
4.2.3	Affymetrix Gene Profiling Reagents	95
4.3	AutoGenomics	96
4.3.1	INFINITI Plus Analyzer	96
4.4	Becton Dickinson	97
4.4.1	BD MAX System	97
4.4.2	BD Viper System	97
4.4.3	BD Affirm VPIII Microbial Identification System	97
4.4.4	BD ProbeTec ET System	98
4.5	Biomerieux	98
4.5.1	NucliSENS EasyQ	98
4.5.2	NucliSENS easyMAG	98
4.6	Cepheid	99
4.6.1	GeneXpert System	99
4.6.2	SmartCycler System	99
4.7	GenMark Dx	99
4.7.1	eSensor XT-8 System	99
4.8	Hologic Gen-Probe	99
4.8.1	PANTHER System	99
4.8.2	TIGRIS DTS System	100
4.9	Illumina	100
4.9.1	MiSeqDx Instrument	100
4.10	Life Technologies/Applied Biosystems	100
4.10.1	QuantStudio Dx Real-Time PCR	100
4.10.2	Veriti Dx PCR Thermal Cycler	100
4.10.3	3500 Dx Genetic Analyzers CS2	101
4.10.4	7500 Fast Dx Real-Time PCR System	101
4.11	Meridian Bioscience	101
4.11.1	Illumipro-10	101
4.12	Nanosphere	102

4.12.1	Verigene System	102
4.13	Qiagen	102
4.13.1	Rotor-Gene Q MDx	102
4.13.2	Rapid Capture System & Hybrid Capture 2 Modular System	103
4.14	Roche	103
4.14.1	COBAS 4800 System	103
4.14.2	COBAS AmpliPrep / COBAS TaqMan System	104
4.14.3	COBAS AMPLICOR Analyzer	104
4.14.4	LightCycler 2.0 Instrument	105
4.15	Siemens	105
4.15.1	VERSANT 440 Molecular System	105
5.	Molecular Diagnostic Testing and Infectious Diseases	106
5.1	Molecular Testing of Infectious Disease Market	106
5.2	HIV Molecular Testing	114
5.2.1	Summary of Assays and Platforms	114
5.2.2	HIV Molecular Diagnostics Market and Technology Trends	118
5.2.2.1	Market Trends	118
5.2.2.2	Technology Trends	119
5.2.2.3	Strategic Recommendations	119
5.3	Hepatitis Molecular Testing	120
5.3.1	Hepatitis B Virus	120
5.3.1.1	HBV Molecular Assays and Platforms	121
5.3.1.2	Hepatitis B Market	125
5.3.2	Hepatitis C Virus	126
5.3.2.1	HCV Molecular Assays	128
5.3.2.2	Hepatitis C Market	132
5.4	Influenza Virus Molecular Testing	135
5.4.1	Assays for Influenza Detection	136
5.4.2	Influenza Molecular Diagnostic Market	139
5.4.2.1	Market Trends	139
5.4.2.2	Technology Trends	140
5.4.2.3	Strategic Recommendations	141
5.5	STD Testing (Chlamydia/Gonorrhea Molecular Diagnostic Testing)	141
5.5.1	CT/NG Testing Competitive Structure and Market Share Analysis	142
5.5.1.1	CT/NG Testing Market Trends	142
5.5.1.2	Technology Trends	143
5.5.1.3	Strategic Recommendations	144
5.5.2	Chlamydia Molecular Diagnostic Testing	144
5.5.2.1	Product Analysis: Instruments and Reagents for Testing Chlamydia	145
5.5.3	Gonorrhea Molecular Diagnostic Testing	147
5.5.4	Product Analysis: Instruments and Reagents	148
5.6	Tuberculosis	151
5.6.1	Product Analysis: Instruments and Reagents	154
5.6.2	Tuberculosis Market	156
5.6.2.1	Market Trends	157
5.6.2.2	Technology Trends	159
5.6.2.3	Strategic Recommendations	159
5.7	Methicillin-Resistant Staphylococcus aureus	160
5.7.1	Product Analysis: Instruments and Reagents	161
5.7.2	MRSA Molecular Diagnostics Market	163
5.7.2.1	Market Trends	165
5.7.2.2	Technology Trends	166
5.7.2.3	Strategic Recommendations	166
5.8	Vancomycin-resistant Enterococci	168

5.8.1	Product Analysis: Instruments and Reagents	169
5.8.2	VRE Molecular Testing Market	170
5.8.2.1	Market Trends	171
5.8.2.2	Technology Trends	171
5.8.2.3	Strategic Recommendations	171
5.9	Herpes Simplex Virus	172
5.10	C. difficile	173
5.11	Cytomegalovirus	173
5.12	Blood Screening	175
5.12.1	Product Analysis: Instruments and Reagents	177
5.12.2	Blood Screening Market	180
5.12.2.1	Market Trends	181
5.12.2.2	Technology Trends	181
5.12.2.3	Strategic Recommendations	182
5.13	Human Papillomavirus	182
5.13.1	Molecular Instruments and Reagents for HPV Detection	184
5.13.2	HPV Market	191
5.13.2.1	North American Market	192
5.13.2.2	European Market	194
5.13.2.3	Market Trends	195
5.13.2.4	Technology Trends	196
5.13.2.5	Strategic Recommendations	198
6.	Cancer Detection Using Molecular Diagnostics	199
6.1	Breast Cancer	200
6.1.2	Breast Cancer Prognostic Assays	202
6.1.2.1	Myriad Genetics (BRACA1 and BRACA2)	204
6.1.2.2	Genomic Health (Oncotype DX)	204
6.1.2.3	InterGenetics, Inc.	208
6.1.2.4	LabCorp (HER-2)	209
6.1.2.5	Clariant, Inc. (GE Healthcare)	211
6.1.2.6	BioTheronostics (AviaraDx)	212
6.1.2.7	Agendia B.V. (MammaPrint)	212
6.1.2.8	Oncogene Science (Wilex)	214
6.1.2.9	Ventana Medical Systems	216
6.1.3	Competition and Comparison of Methods	216
6.1.4	Competitive Structure and Market Share Analysis	217
6.1.4.1	Breast Cancer Molecular Diagnostic Testing Market Size	218
6.1.4.2	Market Forecasts	220
6.1.4.3	Market Drivers and Restraints	220
6.1.4.4	Breast Cancer Molecular Diagnostic Testing Assay Market and Technology Trends	221
6.2	Colorectal Cancer Molecular Diagnostics Market	221
6.2.1	Colon Cancer Testing Platforms	223
6.2.1.1	Genomic Testing	223
6.2.1.2	Screening Test	228
6.2.2	Players in the Colorectal Cancer Space	228
6.2.3	Competitive Structure and Market Share Analysis	234
6.2.3.1	Colon Cancer Molecular Diagnostic Testing Market Size	235
6.2.3.2	Market Forecasts	236
6.2.3.4	Market Drivers and Restraints	237
6.2.3.5	Colon Cancer Molecular Diagnostic Testing Assay Market and Technology Trends	237
6.3	Prostate Cancer Molecular Diagnostics Market	240
6.3.1	Screening for Prostate Cancer	241
6.3.1.1	PSA Screening Test for Prostate Cancer	241
6.3.1.2	PCA3 Screening Test for Prostate Cancer	242

6.3.1.3	Gen-Probe	244	
6.3.1.4	Beckman Coulter (Danaher) Prostate Health Index	246	
6.3.1.5	Opko Health 4KScore	246	
6.3.1.6	Metabolon Prostarix DRE Urine Test	246	
6.3.2	Tests after Positive Biopsy	247	
6.3.2.1	Myriad Genetics (Prolaris)	247	
6.3.2.2	Genomic Health (Genomic Prostate Score)	247	
6.3.2.3	Bostwick Laboratories (ProstaVysion)	247	
6.3.2.4	Metamark Genetics (Biopsy Test)	248	
6.3.3	Tests After Negative Biopsy	248	
6.3.3.1	Mitomics (Prostate Core Test)	248	
6.3.3.2	MDxHealth (Confirm MDx)	249	
6.3.4	Tests After Surgery	249	
6.3.4.1	GenomeDx Sciences (Decipher)	249	
6.3.4.2	Iris International (Nadia ProVue)	250	
6.3.5	Competition and Comparison of Methods	250	
6.3.6	Competitive Structure and Market Share Analysis	251	
6.3.7	Market Drivers and Restraints	252	
6.3.7.1	Market Drivers	252	
6.3.7.2	Market Restraints	252	
6.3.8	Prostate Cancer Molecular Diagnostic Testing Assay Market and Technology Trends	252	
6.3.8.1	Prostate Cancer Molecular Diagnostic Testing Assay Market Trends	252	
6.3.8.2	Prostate Cancer Molecular Diagnostic Testing Assay Technology Trends	253	
6.3.8.3	Prostate Cancer Testing Assay Strategic Recommendations	253	
6.4	Other Cancer Molecular Diagnostic Markets	255	
6.4.1	Bladder Cancer	255	
6.4.2	Lung Cancer	256	
6.4.3	Melanoma	263	
6.5	Molecular Diagnostic Screening Test for Cancer	264	
6.6	Companion Diagnostic Tests for Cancer Therapeutics	265	
7.	Genetics Testing in Molecular Diagnostics	268	
7.1	Key Functions of Molecular Genetic Testing	268	
7.1.1	Diagnostic Testing of Genetic Disorders	269	
7.1.1.1	Common Genetic Disorders	269	
7.1.2	Carrier Testing for Genetic Disorders	269	
7.1.3	Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening	271	
7.1.4	Prenatal/In utero Genetic Testing	273	
7.1.5	Newborn Genetic Screening Tests	273	
7.1.6	Presymptomatic and Predictive Testing for Adult Onset Disorders	274	
7.1.7	Pharmacogenomics	274	
7.1.8	Tissue and Blood Typing	274	
7.1.8.1	Human Leukocyte Antigen Determination	274	
7.1.8.2	Rhesus D Factor Determination	277	
7.1.9	Parentage/Relationship Testing (Paternity Testing)	278	
7.1.10	Genealogical DNA Testing	278	
7.1.11	Criminal and Forensics Testing	279	
7.2	Market Structure and Competitive Situation	279	
7.2.1	Primary Competitors	280	
7.2.2	Commercialization Strategies for Molecular Diagnostic Products	280	
7.2.3	Market Penetration Strategies for Genetic Testing	281	
7.3	Growing Genetic Testing Market Segments	281	
7.3.1	Personalized Medicine and Companion Diagnostics Market	281	
7.3.2	Predictive Molecular Diagnostics Market	283	
7.3.3	Parallel Genetic Tests for Drug Development	283	

7.3.4	Direct-to-Consumer Genetic Testing Market	284	
7.3.5	Detecting Genetic Disorders	285	
7.3.6	Pre-natal Screening	285	
7.3.7	Neonatal Screening	286	
7.3.8	Forensic Testing	286	
7.3.9	Parentage Testing	286	
7.3.10	Blood and Tissue Typing	287	
7.3.11	DNA Sequencing	287	
7.4	Select Diagnostic and Carrier Tests for Genetic Disorders	288	
7.4.1	CombiMatrix Diagnostics' DNAarray™ Pediatric Microarray Oligo 105K	288	
7.4.2	GeneDx's Genetic Testing for Hereditary Disorders	289	
7.4.3	Hologic's Factor V Reagents	289	
7.4.4	Progenika's FH Test	289	
7.4.5	Abbott Molecular's Cystic Fibrosis Genotyping Assay	289	
7.4.6	Counsyl's Universal Genetic Test	290	
7.4.7	Hologic's InPlex® CF Molecular Test	290	
7.4.8	Integrated Genetic's Inheritest Carrier Screen	291	
7.4.9	Luminex's xTAG Cystic Fibrosis (CFTR) v2 Assays	291	
7.4.10	Natera's Natera One Multi-Disease Genetic Carrier Screening Panel	291	
7.4.11	Sequenom's Heredi-T Cystic Fibrosis Carrier Screen Test	292	
7.4.12	Summary of Cystic Fibrosis Tests	293	
7.5	Pre-implantation Genetic Tests	293	
7.5.1	Natera's Preimplantation Genetic Diagnosis Test	293	
7.6	Prenatal/In Utero Molecular Genetic Screening Tests	294	
7.6.1	Cell-Free Fetal DNA Testing	294	
7.6.1.1	Ariosa Diagnostics' Harmony Prenatal Test	294	
7.6.1.2	Natera's Panorama	294	
7.6.1.3	Sequenom's MaterniT21 PLUS Test	295	
7.6.1.4	Verinata Health's verifi Prenatal Test	295	
7.6.2	Molecular Cytogenetic Tests	296	
7.6.2.1	Abbott Molecular's AneuVysion Multicolor DNA Probe Panel	296	
7.6.2.2	CombiMatrix Diagnostics' DNAarray Prenatal Microarrays	296	
7.6.2.3	Signature Genomics' Signature Precision Panel I Prenatal	297	
7.6.2.4	Signature Genomics' Signature PrenatalChip TE (Targeted Enhanced) Microarray	298	
7.6.2.5	Signature Genomics' Signature PrenatalChip OS Microarray	298	
7.7	Newborn Genetic Screening Tests	299	
7.7.1	Screening for Cystic Fibrosis with Molecular Diagnostic Assays	299	
7.7.2	Screening for SCID with the TREC Assay	299	
7.7.2.1	PerkinElmer Genetics	300	
8.	Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics	301	
8.1	The Market	301	
8.1.1	Detection of Helicobacter pylori by PCR	304	
8.1.2	Detection of Escherichia coli 0157	304	
8.1.3	Detection of Enteric Viruses	304	
8.1.4	Industrial Microorganisms	304	
8.2	Molecular Diagnostics Forensics Testing Market	304	
8.2.1	Analysis by PCR-based DNA Typing	306	
8.2.2	Rapid Isolation of DNA for Restriction Fragment Length Polymorphism (RFLP) and PCR	306	
8.2.3	DNA for PCR-STR Typing	306	
9.	Bioterrorism and Molecular Diagnostics	307	
9.1	Introduction	307	
9.2	Current Biological Threat Detection Systems	309	
9.2.1	Use of DNA Microarrays and Biochips for Gene Expression Profiles in BWAs	310	

9.2.2	Advantages and Disadvantages of Host Gene Expression Profiling as a Biothreat Detection	310
9.2.3	Biological Warfare Agents	311
9.2.4	Anthrax	312
9.2.5	Botulinum Toxin	313
9.2.6	Ricin	313
9.2.7	IVD Industry and Bioterrorism Preparedness	313
9.2.8	Brucellosis	314
9.2.9	Cholera	315
9.3	Rapid Lateral Flow Immunoassays	315
9.4	Biosensors	315
9.5	Anthrax in Clinical Samples	317
9.5.1	Rapid Tests	318
10.	Regulatory Requirements	320
10.1	U.S. Food and Drug Administration	321
10.1.1	FDA Labeling Requirements	321
10.1.2	U.S. Government Regulation of Medical Devices	321
10.1.3	FDA's Qualification of Biomarkers	322
10.1.4	FDA's Voluntary Genomic Data Submission	323
10.2	Clinical Laboratory Improvement Act	324
10.3	CLIA Regulations	325
10.4	State Licensing for Service Laboratories	325
10.5	Multivariate Index Assays	326
10.6	FDA Draft Guidance on In Vitro Companion Diagnostic Devices	327
10.7	FDA Draft Guidance on Molecular Diagnostic Instruments with Combined Functions	327
10.8	510(k) Clearance	327
10.9	Pre-Market Approval	328
10.10	Pre-market Approval Application	328
10.11	Laboratory Developed Tests	329
10.12	Analyte Specific Reagents	332
10.13	What Regulatory Guidance is needed for Companion Biomarkers?	333
10.14	IRB Approval in Clinical Trials	334
10.15	CE marking and the European In Vitro Diagnostic Device Directive	334
10.16	De Novo Classification	334
10.17	Research Use Only Reagents	335
10.18	Ethical, Legal and Social Issues Related to the Use of Genetic Information	335
10.19	Regulatory Issues for Direct to the Consumer Genetic Tests	335
10.20	The Genetic Information Nondiscrimination Act of 2008	337
10.21	Genetic Tests and Medical Records	337
10.22	Recommendations by the American College of Medical Genetics and Genomics	337
11.	Reimbursement Issues and Billing Landscape for Molecular Diagnostics Testing	338
11.1	Overview	338
11.1.1	Gap Filling	339
11.2	Trends in Healthcare Reimbursement Practices	340
11.2.1	Molecular Genetics Testing Reimbursement	341
11.3	Medicare Reimbursement Program	342
11.4	Medicare Billing Procedure	343
11.5	CPT Coding Rules for Molecular Diagnostics	345
11.5.1	Former Coding Rules for Molecular Diagnostics	345
11.5.2	Current Coding Rules for Molecular Diagnostics	346
11.5.2.1	Gapfilling	346
11.5.2.2	Reimbursement Delays for Molecular Diagnostics	347
11.6	Revenue Threats	348
11.6.1	Medicare Payment Exceptions	350

11.6.2	Three Areas for Denial of Claims	350
11.7	Bundled Payments for Care Improvement Initiative	350
11.8	Infectious Disease Billing Strategies	351
11.9	Analysis of ROI for MDx Tests for Cancer Using Medicare Reimbursement Rules	352
11.9.1	Reimbursement for Insight Dx, MammaPrint and Oncotype Dx	352
11.9.2	Reimbursement for JAK2 Mutation Testing for Myeloproliferative Neoplasms	353
12.	Company Profiles	354
12.1	Abbott Laboratories	354
12.2	AdvanDx	357
12.3	Agendia	358
12.4	Arcxis Biotechnologies	358
12.5	Agilent Technologies	359
12.6	Ambry Genetics	360
12.7	Atlas Genetics	361
12.8	AutoGenomics, Inc.	361
12.9	Beckman Coulter	362
12.10	Becton, Dickinson and Company	365
12.11	Biodesix	367
12.12	Biohelix Corporation	367
12.13	bioMérieux	368
12.14	Bio-Rad Laboratories	368
12.15	Cancer Genetics, Inc.	370
12.16	Celera (acquired by Quest Diagnostics)	371
12.17	Cepheid	372
12.18	Clariant, Inc. (GE Healthcare)	374
12.19	CombiMatrix Corporation	375
12.20	Cytocell Technologies Ltd.	375
12.21	DiagnoCure, Inc.	376
12.22	Enzo Biochem	376
12.23	Epigenomics	377
12.24	Exact Sciences Corporation	377
12.25	Exagen Diagnostics, Inc.	378
12.26	Exiqon	378
12.27	Genera Biosystems	379
12.28	GenMark Diagnostics, Inc.	379
12.29	Genomic Health	380
12.30	Great Basin Corporation	380
12.31	Hologic	381
12.32	Illumina	385
12.33	IntegenX	386
12.34	InterGenetics, Inc.	386
12.35	LabCorp	386
12.36	Life Technologies Corporation	387
12.37	Luminex	389
12.38	Myriad Genetics, Inc.	391
12.39	Nanosphere	393
12.40	Nanostring	394
12.41	Natera	394
12.42	NetBio	394
12.43	Neogenomics	395
12.44	Nuvera Biosciences	395
12.45	Orion Genomics	395
12.46	PerkinElmer Genetics	396
12.47	Progenika	396

12.48	QIAGEN N.V.	396
12.49	Roche Diagnostics	399
12.50	Rosetta Genomics Ltd.	400
12.51	Seegene	400
12.52	Sequenom, Inc.	401
12.53	Siemens Healthcare Diagnostics (Siemens)	401
12.54	Spartan Bioscience	402
12.55	Thorne Diagnostics	402
12.56	Transgenomic	403
12.57	TrimGen	403
12.58	Trovagene, Inc.	403
12.59	Veredus Laboratories	403
12.60	Veridex	403

INDEX OF FIGURES

Figure 2.1: Segment of Double-Stranded DNA Showing the Base-Pair Relationship	22
Figure 2.2: Schematic of Molecular Diagnostics for Studying Gene Expression in Patients	28
Figure 2.3: The PCR Cycle	34
Figure 2.4: Multiple Displacement Amplification	39
Figure 2.5: Using DNA Microassays to Measure Gene Expression	45
Figure 3.1: Overall Structure of Nucleic Acid Testing Market	56
Figure 3.2: Global Market for Molecular Diagnostics Testing, 2012	60
Figure 3.3: Molecular Diagnostics Market Segmentation by Technology	61
Figure 3.4: Share of Molecular Diagnostics Testing by Application, 2012	63
Figure 3.5: Key Players Market Share in Global Molecular Diagnostics Testing Markets	64
Figure 3.6: FDA Co-developed Products as a Model for Collaboration	71
Figure 5.1: Global Market for Infectious Disease Treatments, 2008-2014	106
Figure 5.2: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018	107
Figure 5.3: U.S. Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018	109
Figure 5.4: Infectious Disease Testing Revenue Market Share of Total U.S. MDx Market, 2012 and 2018	109
Figure 5.5: Infectious Disease Testing Revenue Market Share by Region, 2012 and 2018	110
Figure 5.6: Markers of Acute HCV Infection as a Function of Time after Exposure to Infection	127
Figure 5.7: Pipeline for TB Diagnostics, 2005-2015	154
Figure 5.8: The Development Pipeline for New TB Drugs, July 2012	154
Figure 5.9: U.S. Market Share of MRSA Molecular Diagnostic Market, 2012	164
Figure 5.10: Global Market Share (Excluding U.S.) of MRSA Molecular Diagnostic Market, 2012	165
Figure 5.11: U.S. Market Share of VRE Molecular Diagnostic Market, 2012	171
Figure 5.12: Hybrid Capture 2 (HC2) versus PCR - Analytical Sensitivity and Clinical Sensitivity	187
Figure 5.13: Basic Steps in Hybrid Capture 2 Technology	188
Figure 5.14: U.S. Market Share of HPV Molecular Diagnostic Market, 2012	192
Figure 5.15: Global Market Share (Excluding U.S.) of HPV Molecular Diagnostic Market, 2012	193
Figure 5.16: Market Share Estimates for Molecular Diagnostic HPV Testing, 2012	193
Figure 6.1: HER-2/NEU Protein as a Target in Cancer Therapy	210
Figure 6.2: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Equivocal Results with IHC	211
Figure 6.3: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Results by FISH	211
Figure 6.4: Action of Herceptin in Breast Cancer Patients	212
Figure 6.5: Analysis of Cancer Tissue by Microarray	215
Figure 6.6: Global Market Size and Share of Breast Cancer Molecular Diagnostic Market, 2012	220
Figure 6.7: HNPCC Mutation Increases Risk of Cancer	231
Figure 6.8: APC Mutation Increases the Risk of Cancer	232
Figure 6.9: Prostate-Specific Membrane Antigen	240
Figure 6.10: PCA3 Score Nomogram	243
Figure 6.11: Estimates for PCA3 Test Volume in the U.S., 2005-2012	244
Figure 7.1: Segmentation of the Biomarker Development Market	282

Figure 10.1: Current Regulations for Laboratory Testing	320
Figure 10.2: Existing Regulatory Framework for LDTs	332
Figure 11.1: Reimbursement for Diagnostics in Healthcare Decision Making	341
Figure 11.2: MAC Jurisdiction Map, 2012	347

INDEX OF TABLES

Table 2.1: Key Assay Technologies for Molecular Diagnostics	32
Table 2.2: Emerging Molecular Diagnostic Technologies	32
Table 2.3: DNA Microarray Applications	45
Table 2.4: Companies Involved in Next Generation Sequencing Platforms	48
Table 2.5: Desired Characteristics for Clinical Versus Discovery Next Generation Sequencing	51
Table 3.1: Applications of Molecular Diagnostics Technology Platforms	55
Table 3.2: Global Market for Molecular Diagnostics Testing, 2010-2018	59
Table 3.3: U.S. Market for Molecular Diagnostics Testing, 2010-2018	62
Table 3.4: Share of Molecular Diagnostics Testing by Application, 2012	63
Table 3.5: Key Players and Market Share in the Global Molecular Diagnostics Testing Market	64
Table 3.6: Revenue Model for Molecular Diagnostics Testing	64
Table 3.7: Companies Marketing Multiple Products in Molecular Diagnostics Sector	67
Table 3.8: Companies Marketing Clinical Genotyping Technologies	67
Table 3.9: Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact	72
Table 3.10: Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact	72
Table 3.11: Molecular Diagnostic Testing Market Trends	73
Table 3.12: Molecular Diagnostic Testing Technology Trends	75
Table 3.13: Attractive Growth Areas for Molecular Diagnostic Testing	77
Table 3.14: Molecular Diagnostics Market: Strategic Recommendations on MDx Sector Business Functions	77
Table 3.15: Potential Benefits of Pharmacogenetics	83
Table 3.16: Select Drugs with Commercially Available Pharmacogenetic Tests	85
Table 3.17: Examples of Personalized Medicine in Treatment of Infectious Disease	86
Table 3.18: Documents for Protecting Intellectual Property Rights	90
Table 3.19: Recent Patents Related to PCR, Nucleic Acid Amplification and Sample Prep	92
Table 4.1: Molecular Diagnostic High-Throughput Automated Testing Systems	93
Table 5.1: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018	107
Table 5.2: Molecular Infectious Disease Diagnostics Market: Market Restraints Ranked in Order of Impact	108
Table 5.3: Molecular Infectious Disease Diagnostics Market: Market Drivers Ranked in Order of Impact	108
Table 5.4: U.S. Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018	108
Table 5.5: Molecular Diagnostic Markets for Infectious Disease Testing, 2012	110
Table 5.6: Molecular Diagnostic Markets for Infectious Disease Testing, 2018	111
Table 5.7: Business Factors Influencing Advanced Infectious Disease MDx Testing Services	112
Table 5.8: Key Players in Global Molecular Diagnostics Infectious Disease Testing Market	112
Table 5.9: Summary of Assays for HIV Viral Load Testing	114
Table 5.10: HIV Resistance Testing Recommendations	115
Table 5.11: Commercially Available Molecular Diagnostic Products for HIV Assay	115
Table 5.12: Lower Detection Limits of HBV DNA Assays	122
Table 5.13: Summary of Molecular Diagnostic Assays for Testing HBV	124
Table 5.14: Recommendations for HCV Diagnostic Testing	128
Table 5.15: Commercially Available Molecular Diagnostic Products for HCV Assay	132
Table 5.16: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2012	133
Table 5.17: Commercially Available Molecular Diagnostic Products for Influenza Assay	139
Table 5.18: Major Companies Marketing Chlamydia/Gonorrhea Molecular Diagnostic Tests: Market Size and Share, 2012	142
Table 5.19: Commercially Available Molecular Diagnostic Products for Chlamydia Assay	146
Table 5.20: Commercially Available Molecular Diagnostic Products for Gonorrhea Assay	151
Table 5.21: Commercially Available Molecular Diagnostic Assays for Testing TB	155

Table 5.22: Comparative U.S. Claim Charges for TB Testing by Type, 2012	157
Table 5.23: Global Testing for TB by Testing Type, 2012	157
Table 5.24: Global Testing for TB by Testing Reason, 2012	157
Table 5.25: Commercially Available Molecular Diagnostic Products for MRSA Assay	163
Table 5.26: Major Companies Marketing MRSA Molecular Diagnostic Tests: Market Size and Share, 2012	163
Table 5.27: Commercially Available Molecular Diagnostic Products for VRE Assay	170
Table 5.28: Major Companies Marketing VRE Molecular Diagnostic Tests: Market Size and Share, 2012	170
Table 5.29: Transmission-related Disease Screening from Blood Donor Pools	174
Table 5.30: Principal Blood Screening Products of Hologic Gen-Probe for HIV Assay	177
Table 5.31: Major Companies Marketing Blood Screening Molecular Diagnostic Tests: Market Size and Share, 2012	179
Table 5.32: Qiagen's Digene HC2 High-risk HPV DNA Test	186
Table 5.33: Commercially Available Molecular Diagnostic Products for HPV Assay	191
Table 5.34: Major Companies Marketing HPV Molecular Diagnostic Tests: Market Size and Share, 2012	192
Table 6.1: Companies Marketing Products in the Cancer Molecular Diagnostics Sector	200
Table 6.2: Key Elements for Business Competition in Gene Expression Profiling for Cancer	200
Table 6.3: Key Elements for Future Success in the Gene Profiling for Cancer Segment	201
Table 6.4: Breast Cancer Overview	201
Table 6.5: Overview of ER/PR Testing and Response to Therapy	202
Table 6.6: Key Players in the Breast Cancer Molecular Diagnostic Space	203
Table 6.7: Commercially Available Molecular Diagnostic Products for Breast Cancer Assay	204
Table 6.8: Summary of Strengths, Weaknesses, Opportunities and Threats of the Breast Cancer Molecular Diagnostic Market	204
Table 6.9: Clinical Utility and Health Economic Benefits of Oncotype DX	206
Table 6.10: Oncotype DX Overview	206
Table 6.11: Comparison of Agendia vs. Genomic Health Breast Cancer Tests	207
Table 6.12: Overview of HER2/neu and Herceptin	210
Table 6.13: MammaPrint: Key Features	214
Table 6.14: Oncogene Science Biomarker Group Reagents	215
Table 6.15: Major Laboratory Testing Companies Marketing Breast Cancer Molecular Diagnostic Tests, 2012	218
Table 6.16: Global Market for Breast Cancer Molecular Diagnostic Testing, 2005-2012	219
Table 6.17: U.S. Market for Breast Cancer Molecular Diagnostic Testing, 2005-2012	219
Table 6.18: Global Market Forecast for Breast Cancer Molecular Diagnostic Testing, 2013-2018	221
Table 6.19: U.S. Market Forecast for Breast Cancer Molecular Diagnostic Testing, 2013-2018	221
Table 6.20: Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact	221
Table 6.21: Breast Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact	222
Table 6.22: Colorectal Cancer Overview	223
Table 6.23: KRAS Mutation Assay	224
Table 6.24: KRAS Assays by Analytical Type	226
Table 6.25: KRAS Mutation Analysis Summary	226
Table 6.26: DxS KRAS Mutation Test Summary	227
Table 6.27: KRAS and BRAF in Clinical Use	228
Table 6.28: Product Development Opportunities in Cancer Tumor Types, 2008	228
Table 6.29: Key Players in the Colorectal Cancer Molecular Diagnostic Space	229
Table 6.30: ArcticDx Genetic Test, Colo Risk	233
Table 6.31: NexCourse CRC Test Offering and Treatment Direction	235
Table 6.32: Global Market for Molecular Diagnostic Colon Cancer Testing, 2005-2012	236
Table 6.33: U.S. Market for Molecular Diagnostic Colon Cancer Testing, 2005-2012	236
Table 6.34: Global Market Forecast for Colon Cancer Molecular Diagnostic Testing, 2013-2018	237
Table 6.35: U.S. Market Forecast for Colon Cancer Molecular Diagnostic Testing, 2010-2018	237
Table 6.36: Colon Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact	238
Table 6.37: Colon Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact	238
Table 6.38: Summary of Strengths, Weaknesses, Opportunities and Threats of the Colon Cancer Market	240
Table 6.39: Stages in Prostate Cancer Discovery and Diagnosis	241
Table 6.40: Corporate Players Entering the Prostate Cancer Molecular Diagnostic Space	243

Table 6.41: Gen-Probe Genetic Testing Product Line	247
Table 6.42: Prostate Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact	253
Table 6.43: Prostate Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact	253
Table 6.44: Summary of Strengths, Weaknesses, Opportunities and Threats of the Prostate Cancer Molecular Diagnostic Market	254
Table 6.45: Players in the Bladder Cancer Molecular Diagnostic Space	254
Table 6.46: Lung Cancer Survival Rates	256
Table 6.47: Lung Cancer Facts	256
Table 6.48: Lung Cancer Predictive and Prognostic Markers	260
Table 6.49: Potential of Cancer Biomarkers in Drug Delivery and Development	265
Table 6.50: Barriers to Adoption of Biomarkers in Clinical Use	265
Table 7.1: Common Genetic Disorders	269
Table 7.2: HLA Allele Nomenclature	276
Table 7.3: Comparison of HLA Typing Methods	277
Table 7.4: Diagnostic Companies with Existing Pharma Relationships (market caps under \$5 Billion)	282
Table 7.5: Use of Cancer Biomarkers in Drug Development	283
Table 7.6: Utility of Biomarkers as Companion Diagnostics to Drug Development	284
Table 7.7: Competitors in the Field of Forensic Testing	286
Table 7.8: Competitors in the Field of Identity, Family and Paternity Testing	286
Table 7.9: Comparison of Current Genetic Testing Protocols and Potential Use of Whole Genome Sequencing	288
Table 7.10: Commercial CF-Screening Products	293
Table 7.11: CF Screening Technology Summary	293
Table 8.1: Molecular Diagnostics Methods for Detection of Salmonella in Food	303
Table 9.1: Barriers for Biologics Warfare Monitoring Systems	308
Table 9.2: Technical Problems for PCR Assays for Pathogen Genotyping and Detection	309
Table 9.3: Biological Warfare Agents Identified by PCR Methods	312
Table 9.4: Companies Developing Detection Devices for Biological Warfare Agents	312
Table 10.1: Regulatory Rules that Affect the Ability of a Diagnostic Testing Reagent Company to Conduct Business	320
Table 10.2: Strengths of the 510k Process	328
Table 10.3: Drawbacks of the 510k Process	328
Table 10.4: Focus Areas for the FDA Critical Path Initiative	334
Table 11.1: Factors Determining Third-Party Payment for Molecular Diagnostic Tests	349
Table 11.2: CPT Codes for Molecular Diagnostic Infectious Disease Testing	351
Table 11.3: New CPT Codes for Respiratory Virus Detection	352

1. Overview

1.1 Statement of Report

This report describes the specific segment of the *in vitro* diagnostics (IVD) market known as molecular diagnostics (MDx). In the current medical diagnostics market, molecular diagnostics offers the brightest promise for growth and innovation. The rapid development of this sector of the diagnostics industry has been driven by:

- The confluence of research breakthroughs in genomics such as the human genome project.
- The development of a wide variety of polymerase chain reaction (PCR)-based technology platforms.
- The rise of gene expression profiling.
- New developments in cancer diagnosis and treatment.
- The need for screening the blood supply for infectious diseases.
- Detection of infectious diseases in a hospital setting for intensive care units (ICUs) and other critically ill patients.
- The use of microarrays and multiplexing.

This review analyzes the size and growth of the MDx market, including the factors that influence the various market segments within it, the dollar volume of sales, both in the United States and worldwide. Also examined are:

- PCR technology platforms.
- Clinical applications of nucleic-acid-based testing.
- The market for molecular diagnostic tests.
- Companies participating in this sector.
- New instrumentation, technology platforms and diagnostic lab testing reagents.
- Trends in the MDx industry sector.
- The internal structure of the molecular diagnostics testing sector.

1.2 About This Report

This report:

- Examines all of the generally-accepted clinical analytical activities in use today in the MDx sector. It includes the prevalent clinical measurement devices and the accompanying reagents and supplies as utilized in hospitals, clinics, large reference laboratories and doctor's offices.
- Discusses the potential benefits of the MDx market for various sectors of the medical and scientific communities, and it assesses the market drivers and bottlenecks from the perspective of these communities.
- Establishes the current total market size and future growth of the MDx market and analyzes the current size and growth of various segments.
- Assesses various business models in MDx and provides strategic recommendations for near-term business opportunities.
- Examines the products offered and roles played by companies that have invested significantly in this market, and it provides current and forecasted market shares by these companies.

1.3 Scope of the Report

The goal of this study is to review the market for MDx testing equipment and supplies using reagents and instruments for analysis of individual components in body tissues and fluids. Toward this goal, this review answers the following key questions:

- Which companies are utilizing cutting-edge technologies to develop, validate and market molecular tests for clinical use?
- What are the current impediments to incorporating promising molecular tests into clinical practice?
- Which new molecular diagnostics tests show the most promise for approval?
- What are the economic challenges to gaining approval?
- How can regulatory oversight drive approval and adoption of new technologies?
- Which alliances show the greatest synergy in bringing MDx tests to market?
- Which shared technologies are driving the most encouraging development?

This examination surveys most of the biotech companies known to be currently marketing, manufacturing or developing instruments and reagents for the MDx market, in both the U.S. and the world. Each leading company is discussed in depth, with sections on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.

The U.S., Europe and Japan, the world's three largest molecular diagnostics markets, are the focus of this report. Primary attention is paid to the hospital market segment and, separately, to the instruments, reagents and supplies marketed by the major companies in this segment. Market size, growth rates and market components for instruments, reagents, controls and consumables used in this area are also analyzed.

This analysis emphasizes the companies that are actively developing and marketing clinical laboratory instrumentation, reagents and supplies for performing molecular diagnostics tests. The emphasis in this report is on the clinical use of MDx tests.

1.4 Objectives

The main objectives of this analysis are:

- Identifying viable technology drivers through a comprehensive look at platform technologies for MDx, including probe-based nucleic acid assays, microarrays and sequencing.
- Obtaining a complete understanding of the chief MDx tests—*i.e.*, predictive, screening, prognostic monitoring, pharmacogenomic and theranostic tests—from their basic principles to their applications.
- Discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology.
- Focusing on global industry development through an in-depth analysis of the major world markets for MDx including growth forecasts.

One goal of this study is to review the market for molecular diagnostics testing equipment and supplies using reagents and instruments for analysis of individual components in blood, serum or plasma. Many new techniques in this space depend on the emerging developments in the genomic and proteomic spaces. The report also defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. The subsections of each market segment, including: commercial, hospital and specialty laboratories are examined. Additionally, the factors that influence purchases are also discussed.

This report will do the following:

- Assess the MDx market drivers and bottlenecks from the perspective of the medical and scientific communities.
- Discuss the potential benefits of the MDx market for various sectors of the medical and scientific community.

- Establish the current total market size and future growth of the molecular diagnostics market and analyze the current size and growth of various segments.
- Provide current and forecasted market shares by the company.
- Provide strategic recommendations for near-term business opportunities.
- Assess current commercial uses of the MDx market.
- Review the molecular diagnostics business models.

The emphasis in this report is on the clinical use of molecular diagnostics tests. The reader should consult other TriMark Publications reports on the TriMark Publications website for detailed discussions of important individual market segments related to the molecular diagnostics market or routine testing. In addition to this report, TriMark Publications offers a complete suite of market reports aimed at the molecular diagnostic space including: *Molecular Diagnostics in Infectious Disease Testing*, *Molecular Diagnostics in Cancer Testing* and *Molecular Diagnostics in Genetic Testing*.

1.5 Methodology

The author of this report holds a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in science writing and as a medical industry analyst. He has over 40 years of experience as a director in laboratory testing and instrument and reagent development technology, as well as extensive experience in senior level positions in biotech and medical service companies. The editor of this report holds a Master's in immunology and has substantial experience in science writing and as a medical industry analyst. She also has many years of laboratory experience and has conducted laboratory testing and instrument and reagent development for biotech companies.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

1.6 Executive Summary

Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added and accepted by the clinical community as CE marked and FDA approved tests. The technologies that come under the umbrella of MDx include first-generation amplification, DNA probes, second-generation biochips and microfluidics, and next-generation signal detection, biosensors and molecular labels. These technologies are profoundly influencing the discovery of new therapeutic molecules, the screening and diagnosis of patients, and the optimization of drug therapy during treatment. Over the past several years, this rapidly evolving field has seen several fascinating developments, including:

- Impact on pharmacogenomics and molecular epidemiology.
- Integration into central lab and point-of-care (POC) clinical practice.
- Impact on proteomics.
- Integration into therapeutics and diagnostics.
- Development of lab-on-a-chip devices.
- Novel relevant technologies, *e.g.*, new ways of labeling and signal detection.
- Gene expression profiling for cancer.
- High throughput detection of infectious disease in donated blood supplies.
- Improved detection of infectious disease.
- New assays for genetic diseases.

In [REDACTED], an estimated [REDACTED] MDx tests were performed at U.S. hospitals, clinics and laboratories, a figure that is projected to reach [REDACTED] in [REDACTED]. The following factors are driving the change from older technology to molecular testing:

- New technologies that permit the necessary quality control and data capture from PCR-based tests.
- Broader menu of available DNA-based tests.
- A greater understanding of the human genome.
- New developments in genomics.

- Exquisite sensitivity and accuracy of PCR-based testing.
- The confluence of research breakthroughs in genomics such as the human genome project.
- The development of a wide variety of PCR-based technology platforms.
- The rise of gene expression profiling.
- New developments in cancer diagnosis and treatment.
- The need for screening the blood supply for infectious diseases.
- Detection of infectious disease.
- The use of microarrays and multiplexing.

More than [REDACTED] companies market products in MDx. Most of these are relatively small, with annual sales between \$[REDACTED] and \$[REDACTED]. However, many major diagnostics companies, such as Abbott Laboratories, Siemens and Roche Diagnostics, have substantial market shares in each category of the MDx and dominate the market. A major outlet for novel diagnostics tests is through original equipment manufacturer (OEM) agreements with global platform suppliers such as Abbott Laboratories, Siemens, Beckman Coulter and Roche. Small and medium-size companies with innovative products have great opportunity for success in the field of MDx. This market segment is characterized by unprecedented growth rates, which stand in contrast with the low or even negative growth rates of mature laboratory-testing segments in fields such as hematology and microbiology. For this reason, mergers and acquisitions (M&As) activity is quite high in the MDx sector.

With the great potential for new testing modalities, infectious disease testing applications are currently paving the way, but there will also be applications in pharmacogenetics, cytogenetics, predisposition diagnostics and molecular cancer diagnostics. The molecular diagnostics industry is built around several basic competing technology platforms:

- PCR (polymerase chain reaction)
- TMA (transcription mediated amplification)
- Target amplification (MDA & MALBAC)
- Nucleic acid sequence amplification (NASBA)
- Ligase chain reaction (LCR)
- Branched chain reaction (bDNA)
- Gene sequencing (Next Generation Sequencing)
- Fluorescence *in situ* hybridization (FISH)
- DNA and oligonucleotide microarrays and chips

Worldwide, approximately \$[REDACTED] was spent on MDx tools, assays and other products in [REDACTED]. Of this amount, approximately [REDACTED]% was spent on assays used for testing infectious diseases such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV). The remaining [REDACTED]% was spent for other products, such as those used in genetic testing or cancer diagnosis and treatment. The global MDx market is forecast to grow \$[REDACTED] by the end of [REDACTED]. As the MDx market continues to grow, TriMark expects human genetic testing, pharmacogenomics, and cancer testing to represent an increasingly larger percentage of this annual amount in the near future.

The molecular diagnostics testing market in the U.S. is the largest and most highly developed in the world. This market segment will significantly outperform the overall IVD market in the U.S., with sales of the U.S. MDx market growing from \$[REDACTED] in [REDACTED] to \$[REDACTED] in [REDACTED] (a CAGR of [REDACTED]%). European MDx market revenues are forecast to increase from \$[REDACTED] in [REDACTED] to \$[REDACTED] in [REDACTED], with a growth rate of [REDACTED]%. The Japanese MDx market was at \$[REDACTED] in [REDACTED]. The projected growth rate is [REDACTED]% per year through [REDACTED], to reach almost \$[REDACTED].

The global market for nucleic acid testing of infectious diseases was estimated to be \$[REDACTED] by the end of [REDACTED]. With unsustainable high growth rates (about [REDACTED]% per year) and the dwindling supply of new high volume infectious diseases, this market segment should slow and mature during the forecast period. The largest segment of the PCR probe market for detection of infectious disease is HIV testing. The U.S. molecular diagnostic HIV testing market is estimated to be \$[REDACTED] per year; globally it is a \$[REDACTED] market. As a supplement to the HIV testing market, the market for determining viral load (the amount of virus in a person's blood) is beginning to grow, as

physicians are using the quantity of HIV virus in the blood as a marker for the effectiveness of antiviral therapy for acquired immunodeficiency syndrome (AIDS). Another significant area of infectious disease probe-based testing is sexually transmitted disease (STD) assessment.

The fundamental restructuring of healthcare delivery—such as downward price pressures and reimbursement cuts—occurring on an international level is impeding the entire diagnostics market, including the MDx sector. To be successful in the marketplace, tests must be novel, cost-competitive, clinically-relevant, reimbursable and capable of being conducted by lower-skilled technicians. This is particularly troublesome for the high-priced, technically difficult molecular diagnostic tests.

The use of molecular-based diagnostic solutions continues to expand to other diseases. For example, the viral load monitoring and genotyping techniques that have increased the life expectancy of HIV-infected patients have emerged as valuable tools for managing those patients infected with HCV. The molecular diagnostics market includes an extensive list of innovative products and tests. New developments, such as gene sequencing and nucleic acid amplification, have revolutionized the IVD industry in general. The future success of companies in the molecular diagnostics space depends on the speed at which they can find expanded applications for assays. For example, increasing insight into the ways in which genes influence a pathogen's response to therapy is ensuring tremendous growth in pharmacogenomics. Collaborations between diagnostics and pharmaceutical companies are expected to drive sales of both products. The dynamic U.S. molecular diagnostics market is highlighted by the growth of the cancer diagnostics and pharmacogenomics sectors. Changes in the industry include substantial moved to reagent driven sales over instrument intensive sales.

The largest market opportunities for PCR-based products will be in:

- Molecular clinical diagnostics of infectious diseases.
- Genomics and life science exploration of genetic codes as related to single-nucleotide polymorphisms (SNPs) for diseases.
- Drug discovery and pharmacogenomics.
- Cytogenetics.
- Personalized medicine and theranostics.

Additional products are being developed for areas such as infectious diseases, cancers, human leukocyte antigen (HLA) testing and genetic testing. A critical need exists for standardizing pre-analytical solutions, such as sample collection, stabilization, purification and handling. The clinical diagnostics segment is the fastest-growing part of PCR and molecular detection, at more than █% per year in reagent sales. As an example of the important trends in molecular diagnostics, TriMark believes the field of pharmacogenomics will become increasingly important in clinical trials and patient care. Through resequencing and genotyping technologies, DNA probe arrays could significantly reduce the cost and time required for high-volume polymorphism analysis, which is now performed using more labor-intensive techniques. The ability to predict which therapies are most likely to be effective for certain patients would constitute a powerful advance in diagnostic areas such as oncology.

Many drug companies without large diagnostic laboratories are concerned that genetic testing might upset the business models underlying many of their most successful products. Even as they have begun experimenting with pharmacogenomics, these companies are concerned that the FDA might use their data to limit the target patient population for potential blockbuster drugs. In view of this, major drug companies are likely to welcome a firm signal from the FDA that will reduce the questions surrounding this new field.

In another major trend, DNA microarrays have become indispensable tools in pharmacogenomics, toxicogenomics, developmental biology, cancer research and many other areas. A microarray is a collection of miniaturized test sites arranged on a surface that permits many assays to be performed in parallel. TriMark believes that nucleic acid testing (NAT) diagnostic assays will be used in the field of pharmacogenomics to screen patients prior to administering new drugs. The molecular clinical diagnostics sector can be divided into five main market opportunities:

- *Infectious Diseases*: This is the oldest and largest market opportunity, which still maintains good projected growth of up to █% CAGR. The actual growth rate may be higher if diagnostics-prescription applications emerge and drive incremental growth. It remains an exciting market, and any business that plans to be a player in nucleic acid testing needs to be involved here at some level.
- *Genetics*: The standard applications being followed in the field of genetics today include areas such as cardiovascular testing (which is being pursued almost universally), factor-5 and factor-2. Also, there are several applications, such as for cystic fibrosis and thrombophilia disorders. (Luminex xTAG[®] Cystic Fibrosis 39 Kit v2.)
- *Pharmacogenomics*: This is a separate market opportunity because it is technically more difficult to genotype a specific drug-metabolizing enzyme. Tests in this market may be a single test or a collection of perhaps a dozen different tests. Furthermore, the market relies on both nucleic acid technology and good bioinformatics.
- *Cancer*: Although current cytology applications use the FISH technique for cancer testing applications, new technologies based upon DNA/PCR are emerging such as the comparative genomic hybridization (CGH) array, and other array technologies, that are experiencing strong growth.
- *Blood Screening*: Blood screening for infectious disease.

Testing for chlamydia/gonorrhea, human papillomavirus (HPV), HIV and HCV viral load represents nearly █% of the total molecular diagnostic test volume in the U.S. Two of the biggest growth drivers are the continued expansion of cervical screening for HPV infection and anticipated growth in testing for hospital acquired infections (HAI). In the genetic testing segment, an estimated █ tests were performed in █; most for cystic fibrosis and thrombophilia disorders. While existing genetic disorder tests will have slow to moderate growth during the forecast period, the continued discovery of disease related mutations, and the trend to direct-to-consumer (DTC) genetic testing may support the growth of the genetic testing landscape in the future.

The cancer testing segment, while small in comparison to infectious disease areas of molecular testing, will experience strong growth, as will the continued emergence of gene expression profiling and companion diagnostic tests for use in patient stratification and therapy selection. These tests are receiving premium pricing because of their high clinical value. There is strong growth in the use of FISH technology for cancer testing applications. Most cytogenetic labs use CGH arrays or plan to adopt use of CGH arrays in the near future. Clinical laboratories continue to expand their testing menus for molecular diagnostics with rapid additions of both new tests and technology platforms.

Geographically, the molecular diagnostic testing market is largely located in the U.S. and Europe, and to a lesser extent in Japan. However, there is a growing market in the so called BRIC countries as well. Latin America and the Pacific Rim countries as expected to have significant emergent markets in MDx by █ and thereafter.